NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases... Show more
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics built on its NMDA receptor platform for central nervous system disorders, with a focus on suicidal depression, chronic pain, and post-traumatic stress disorder. Its lead candidates are NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRX-100 holds Fast Track Designation for suicidal ideation in depression, while NRX-101 holds Breakthrough Therapy Designation for suicidal bipolar depression.
The company also operates HOPE Therapeutics, a network of interventional psychiatry clinics, and its NRx Defense Systems subsidiary, which pursues federally funded programs applying NRX-101 alongside robotic transcranial magnetic stimulation. Investors follow NRXP primarily for its path toward a first commercial drug launch and its potential to address the ongoing U.S. shortage of injectable ketamine.
Over the last 30 days, NRXP declined approximately 17.6%, from a closing price of $2.89 on October 8, 2026, to $2.38 on November 6, 2026. The decline was not linear: the shares traded in a range near $2.85 to $2.95 through mid-October before a series of sharp, high-volume down days in late October and early November, punctuated by a brief recovery toward $2.49 on November 4.
The longer trend has been weaker still. From a close of $3.35 on August 10, 2026, NRXP has fallen roughly 29% over the trailing three months. In early August the stock briefly spiked above $4 intraday before settling back, and it has trended lower since, reflecting persistent selling pressure even amid positive regulatory developments.
The most consequential event of the period was the FDA's October 30 approval of NRx's preservative-free ketamine injection for the U.S. pain and anesthesia markets, delivered ahead of the November 10 GDUFA goal date. Despite the milestone, the stock fell sharply on the news, closing down roughly 14% on exceptionally heavy volume as investors locked in gains following a premarket surge, a pattern consistent with a "sell the news" reaction.
Sentiment was also pressured earlier in the month. On October 20, UBS downgraded the shares to a Sell rating from Buy. Around the same time, a New York Times report and related allegations over whether the company had withheld toxicity data on the preservative benzethonium chloride drew a public rebuttal from management, which described the claims as unfounded and reiterated that its ketamine formulation is preservative-free. These developments added uncertainty even as Wolfe Research initiated coverage with an Outperform rating on October 15 and Ascendiant Capital Markets maintained a Buy and raised its price target at the start of October.
The multi-month downtrend reflects a combination of fundamentals and financing concerns. Second-quarter 2026 results, reported in August, showed a net loss of $0.18 per share that was wider than consensus estimates, alongside a revenue miss, reinforcing the company's still-pre-commercial status. Although NRx ended June with about $26.7 million in cash and continues to use an at-the-market equity facility, the risk of future dilution has remained an overhang for a small-cap company without meaningful product revenue.
Against that backdrop, the company has advanced several substantive programs. In late September, NRx Defense Systems was awarded an initial contract of roughly $11.2 million from DARPA to evaluate robotic TMS combined with NRX-101 in treatment-resistant depression. The ketamine ANDA also progressed through first-cycle review, manufacturing process validation, and two-year stability data during the quarter. These developments, however, have so far been outweighed by selling pressure and broader risk-off sentiment in the speculative biotech space.
Tickeron's Trending AI Robots page curates a selection of the platform's top-performing automated trading strategies. While Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, only the most relevant and consistently strong performers are featured in this section. The bots vary widely by strategy, holding timeframe, and performance metrics, giving traders a way to compare different quantitative approaches in one place. For investors looking to complement their own research with data-driven, algorithmic signals, the page offers a practical starting point for evaluating automated trading tools.
Looking ahead, the most important near-term catalyst is the commercial execution of the newly approved preservative-free ketamine, including launch supply and initial sales uptake. Investors should also monitor the New Drug Application pathway for NRX-100 as a branded treatment for depression, which management has indicated could progress toward a 2027 decision, as well as enrollment and early readouts from the federally funded MIND1 and SPARC-TMS trials of NRX-101.
Financial factors will remain central: upcoming quarterly results, cash runway, and any additional equity financing that could dilute existing holders. Competitive dynamics in the ketamine and depression markets, including established products such as Johnson & Johnson's Spravato, also matter. As with any clinical-stage company, regulatory outcomes and trial data carry meaningful risk, and the stock may remain volatile regardless of individual milestones.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Oscillator for NRXP moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 35 of the 41 cases the stock moved higher. This puts the odds of a move higher at 85%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for NRXP just turned positive on November 06, 2026. Looking at past instances where NRXP's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
Following a +14.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXP advanced for three days, in 191 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
NRXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRXP as a result. In 76 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 50-day moving average for NRXP moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NRXP entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NRXP's P/B Ratio (-606.141) is very low in comparison to the industry average of (3.498). P/E Ratio (-4.667) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (29.851) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. NRXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
is a blank check company, which engages in a stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology